• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 201

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a Psychedelic Informed World

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab

Genesee Herzberg — Ketamine Truths, MDMA Hopes, and the Work of Integration

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals...

Wesana Health Reports Q3 2021 Financial Results

Awakn Life Sciences Strengthens Executive Leadership Team

PT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your...

MindMed and Liechti Lab publish first human data on the interacting...

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic...

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Red Light Holland Reports Second Quarter 2021 Results

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing &...

1...200201202...301Page 201 of 301

EDITOR PICKS

Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action

Ayahuasca Podcast: Joe Moore – Safe Access, Breathwork and Building a...

In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©